GIANFILIPPO, GIULIA Statistiche
GIANFILIPPO, GIULIA
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer
2021-01-01 Fogli, S.; Gianfilippo, G.; Cucchiara, F.; Del Re, M.; Valerio, L.; Elisei, R.; Danesi, R.
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers
2020-01-01 Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M.
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA
2020-01-01 Del Re, M.; Petrini, I.; Mazzoni, F.; Valleggi, S.; Gianfilippo, G.; Pozzessere, D.; Chella, A.; Crucitta, S.; Rofi, E.; Restante, G.; Miccoli, M.; Garassino, M. C.; Danesi, R.
Circulating biomarkers of response to immunotherapy in cancer treatment
2019-01-01 Re, M. D.; Gianfilippo, G.; Crucitta, S.; Addeo, A.; Van Schaik, R. H. N.; Danesi, R.
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers
2019-01-01 Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M.
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy
2019-01-01 Crucitta, S.; Restante, G.; Del Re, M.; Bertolini, I.; Bona, E.; Rofi, E.; Fontanelli, L.; Gianfilippo, G.; Fogli, S.; Stasi, I.; Ghilli, M.; Fontana, A.; Danesi, R.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer | 1-gen-2021 | Fogli, S.; Gianfilippo, G.; Cucchiara, F.; Del Re, M.; Valerio, L.; Elisei, R.; Danesi, R. | |
| Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers | 1-gen-2020 | Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M. | |
| Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA | 1-gen-2020 | Del Re, M.; Petrini, I.; Mazzoni, F.; Valleggi, S.; Gianfilippo, G.; Pozzessere, D.; Chella, A.; Crucitta, S.; Rofi, E.; Restante, G.; Miccoli, M.; Garassino, M. C.; Danesi, R. | |
| Circulating biomarkers of response to immunotherapy in cancer treatment | 1-gen-2019 | Re, M. D.; Gianfilippo, G.; Crucitta, S.; Addeo, A.; Van Schaik, R. H. N.; Danesi, R. | |
| Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers | 1-gen-2019 | Rofi, E.; Del Re, M.; Arrigoni, E.; Rizzo, M.; Fontanelli, L.; Crucitta, S.; Gianfilippo, G.; Restante, G.; Fogli, S.; Porta, C.; Danesi, R.; Schmidinger, M. | |
| Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy | 1-gen-2019 | Crucitta, S.; Restante, G.; Del Re, M.; Bertolini, I.; Bona, E.; Rofi, E.; Fontanelli, L.; Gianfilippo, G.; Fogli, S.; Stasi, I.; Ghilli, M.; Fontana, A.; Danesi, R. |